title: p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.
abstract: The high prevalence of bladder cancer and its recurrence make it an important target for chemoprevention. About half of invasive urothelial tumors have mutations in p53. We determined the chemopreventive efficacy of a p53-stabilizing agent, CP-31398, in a transgenic UPII-SV40T mouse model of bladder transitional cell carcinoma (TCC) that strongly resembles human TCC. After genotyping, six-week-old UPII-SV40T mice (n = 30/group) were fed control (AIN-76A) or experimental diets containing 150 or 300 ppm of CP-31398 for 34 weeks. Progression of bladder cancer growth was monitored by magnetic resonance imaging. At 40 weeks of age, all mice were killed; urinary bladders were collected to determine weights, tumor incidence, and histopathology. There was a significant increase in bladder weights of transgenic versus wild-type mice (male: 140.2 mg vs 27.3 mg, P < .0001; female: 34.2 mg vs 14.8 mg, P < .0001). A significant decrease in the bladder tumor weights (by 68.6-80.2%, P < .0001 in males and by 36.9-55.3%, P < .0001 in females) was observed in CP-31398-treated mice. Invasive papillary TCC incidence was 100% in transgenic mice fed control diet. Both male and female mice exposed to CP-31398 showed inhibition of invasive TCC. CP-31398 (300 ppm) completely blocked invasion in female mice. Molecular analysis of the bladder tumors showed an increase in apoptosis markers (p53, p21, Bax, and Annexin V) with a decrease in vascular endothelial growth factor in transgenic mice fed CP-31398. These results suggest that p53-modulating agents can serve as potential chemopreventive agents for bladder TCC.
authors.affiliation: Department of Medicine, Hem-Onc Section, PC Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Venkateshwar
authors.initials: V
authors.lastname: Madka
authors.forename: Yuting
authors.initials: Y
authors.lastname: Zhang
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.forename: Altaf
authors.initials: A
authors.lastname: Mohammed
authors.forename: Puneet
authors.initials: P
authors.lastname: Sindhwani
authors.forename: Stan
authors.initials: S
authors.lastname: Lightfoot
authors.forename: Xue-Re
authors.initials: XR
authors.lastname: Wu
authors.forename: Levy
authors.initials: L
authors.lastname: Kopelovich
authors.forename: Chinthalapally V
authors.initials: CV
authors.lastname: Rao
mesh_terms: D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000235:genetics / Q000378:metabolism; D002295:Carcinoma, Transitional Cell / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007150:Immunohistochemistry; D008279:Magnetic Resonance Imaging; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D015394:Molecular Structure; D009361:Neoplasm Invasiveness; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*; D001743:Urinary Bladder / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D060170:Uroplakin II / Q000235:genetics / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism
chemical_list: D000952:Antigens, Polyomavirus Transforming; C493957:Cdkn1a protein, mouse; D050759:Cyclin-Dependent Kinase Inhibitor p21; D011743:Pyrimidines; D016159:Tumor Suppressor Protein p53; C554659:Upk2 protein, mouse; D060170:Uroplakin II; D051028:bcl-2-Associated X Protein; C402665:CP 31398
references.citation: Int J Urol. 2013 Feb;20(2):251-5
references.pmid: 22905972
references.citation: Oncogene. 2003 Nov 13;22(51):8233-45
references.pmid: 14614447
references.citation: Mol Cancer Ther. 2013 Feb;12(2):121-30
references.pmid: 23269072
references.citation: Cancer Biol Ther. 2002 Jan-Feb;1(1):47-55
references.pmid: 12174820
references.citation: Int J Cancer. 2008 Jan 1;122(1):155-64
references.pmid: 17893872
references.citation: Am J Pathol. 2000 Sep;157(3):805-13
references.pmid: 10980120
references.citation: Science. 1999 Dec 24;286(5449):2507-10
references.pmid: 10617466
references.citation: Urology. 2008 Sep;72(3):470-3
references.pmid: 18533230
references.citation: Curr Opin Oncol. 2008 Jan;20(1):90-6
references.pmid: 18043262
references.citation: Cancer Res. 2010 Aug 15;70(16):6566-76
references.pmid: 20682800
references.citation: Korean J Urol. 2012 Nov;53(11):800-6
references.pmid: 23185674
references.citation: Oral Oncol. 2011 Jan;47(1):8-15
references.pmid: 21109480
references.citation: Lancet. 1993 Aug 21;342(8869):469-71
references.pmid: 8102431
references.citation: J Urol. 2001 Oct;166(4):1275-9
references.pmid: 11547057
references.citation: Urol Clin North Am. 1992 Nov;19(4):735-46
references.pmid: 1279877
references.citation: Nat Cell Biol. 2000 Oct;2(10):737-44
references.pmid: 11025665
references.citation: Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3248-55
references.pmid: 18089718
references.citation: Cancer Res. 2000 Jul 1;60(13):3655-61
references.pmid: 10910082
references.citation: Jpn J Clin Oncol. 2012 Jul;42(7):569-77
references.pmid: 22593639
references.citation: Cancer Res. 1994 Feb 1;54(3):784-8
references.pmid: 8306342
references.citation: Clin Cancer Res. 2000 Jul;6(7):2635-43
references.pmid: 10914704
references.citation: Cancer Res. 2008 Sep 15;68(18):7670-5
references.pmid: 18794156
references.citation: Semin Surg Oncol. 1992 Sep-Oct;8(5):274-8
references.pmid: 1462097
references.citation: Plant Foods Hum Nutr. 2012 Sep;67(3):235-41
references.pmid: 22961050
references.citation: Cancer Res. 1997 Dec 1;57(23):5281-5
references.pmid: 9393750
references.citation: Cancer Res. 2000 Oct 15;60(20):5599-602
references.pmid: 11059745
references.citation: Cancer Res. 1999 Jul 15;59(14):3512-7
references.pmid: 10416618
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):555-63
references.pmid: 12050097
references.citation: Hum Pathol. 1995 Sep;26(9):970-8
references.pmid: 7672797
references.citation: Eur Urol. 2013 Apr;63(4):724-32
references.pmid: 22925575
references.citation: Cancer Res. 2009 Oct 15;69(20):8175-82
references.pmid: 19826045
references.citation: Cancer Gene Ther. 2001 Mar;8(3):193-202
references.pmid: 11332990
references.citation: J Clin Invest. 2007 Dec;117(12):3753-64
references.pmid: 18060030
references.citation: J Urol. 1977 May;117(5):583-90
references.pmid: 859200
references.citation: Adv Cancer Res. 2007;97:321-38
references.pmid: 17419952
references.citation: Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2002-7
references.pmid: 8700875
references.citation: PLoS One. 2012;7(6):e38808
references.pmid: 22719951
references.citation: Toxicol Pathol. 1998 Jan-Feb;26(1):121-7
references.pmid: 9502394
references.citation: Apoptosis. 2013 Mar;18(3):337-46
references.pmid: 23238993
references.citation: Cancer Res. 2001 Oct 15;61(20):7449-55
references.pmid: 11606379
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Int J Urol. 2003 Mar;10(3):160-6
references.pmid: 12622713
references.citation: Jpn J Cancer Res. 2002 Jan;93(1):42-9
references.pmid: 11802807
references.citation: Urol Oncol. 2004 Jan-Feb;22(1):1-6
references.pmid: 14969795
references.citation: Oncogene. 2005 Nov 21;24(52):7729-45
references.pmid: 16299533
references.citation: Int J Cancer. 2008 Nov 15;123(10):2254-9
references.pmid: 18712722
references.citation: J Natl Cancer Inst. 1998 Jul 15;90(14):1072-9
references.pmid: 9672255